KORU Medical Systems(KRMD) - 2023 Q3 - Earnings Call Presentation

6 • Freedom60 with PFS is preferred by 78% of patients • 70% of patients are on >50 mL 15 Total Collaborations | +1/-1 in Q3 2023 $2.5B TAM(1) | 2M(2) Global Patient Population 2025 7 8 9 Submitted for regulatory approval 10 Back Order$0.3 $7.8$7.0 (10%) $5.9$5.8 $1.1$1.1 $0.2$0.8 Q3 2022 Q3 2023 Novel Therapies International Core • Decreased 2% y/y, +6% YTD • Lower consumable volumes as compared to prior year when a $0.3M backorder was cleared. • Outpaced U.S. Rx script declines driven by increased vo ...